Screen LibraryEconomic dimensions of personalized and precision medicine /
"Advances in human genetics have begun to yield clinical benefits through the development of Precision Medicine (PM). The benefits of this innovation are promising, both through application of constitutional genetics detecting mutations that affect the risk of disease and tumor genetics, and ma...
Saved in:
| Group Author: | ; ; |
|---|---|
| Published: |
The University of Chicago Press,
|
| Publisher Address: | Chicago : |
| Publication Dates: | 2019. |
| Literature type: | Book |
| Language: | English |
| Series: |
National Bureau of Economic Research conference report
|
| Subjects: | |
| Summary: |
"Advances in human genetics have begun to yield clinical benefits through the development of Precision Medicine (PM). The benefits of this innovation are promising, both through application of constitutional genetics detecting mutations that affect the risk of disease and tumor genetics, and malignancy-causing mutations susceptible to targeted therapies. While PM may ultimately be used in all aspects of medicine, to date, the most fruitful applications have been in maternal-fetal medicine and cancer. However, due to the complexity and cost of developing these innovations, and to privacy issues, advancing PM is a challenge in traditional clinical, reimbursement, and regulatory landscapes. Although much of the literature focuses on challenges in relating constellations of mutations to the identification of actual current or potential disease states, and to the efficacy of treatments, diffusion of PM also depends on many non-clinical factors. For example, how will information on accurate diagnosis and treatment success be disseminated, and who will bear the cost? How might physician training change to incorporate genetic, probability, statistics, and economic considerations? How can patients reconcile with the ethical and privacy concerns related to the availability of genetic information? Will the era of PM yield still more disparities in access to care? Will cost-effectiveness analysis need to change to better take into account patient heterogeneity? This volume explores the intersection of the scientific, clinical, and economic factors to consider in developing PM. We explore the theoretical and historical underpinnings of PM, discuss implementation issues, and present examples of real-world applications."-- |
| Item Description: | "The event [conference] took the form of two sessions: a preconference at the Columbia University Italian Academy in New York City in September 2016, followed by a two-day research workshop at Shutters on the Beach Hotel in Santa Monica, CA, in September 2017."--Page ix. |
| Carrier Form: | ix, 349 pages : illustrations, forms ; 24 cm. |
| Bibliography: | Includes bibliographical references and indexes. |
| ISBN: |
9780226611068 (cloth : alkaline paper) : 022661106X (cloth : alkaline paper) 9780226611235 (ebook) 022661123X (ebook) |
| Index Number: | RM301 |
| CLC: | R96-532 |
| Call Number: | R96-532/E195/2017 |
| Contents: |
The Economic Value and Pricing of Personalized Medicine / Therapeutic Translation of Genomic Science: Opportunities and Limitations of GWAS / The Value of Pharmacogenomic Information / The Information Pharms Race and Competitive Dynamics of Precision Medicine: Insights from Game Theory / Characterizing the Drug Development Pipeline for Precision Medicines / Cost Sharing in Insurance Coverage for Precision Medicine / Measuring the Potential Health Impact of Personalized Medicine: Evidence from Multiple Sclerosis Treatments / Physicians' Financial Incentives to Personalize Medicine / Economic Dimensions of Personalized and Precision Medicine in Asia: Evidence from Breast Cancer Treatment in Taiwan / The Value of Cytochrome P450 2C19 Pharmacogenomic Information for Patients Receiving Clopidogrel Therapy Following a Major Cardiovascular Event: Evidence from Geisinger / Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies / |